chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Neck pain; Jaw pain; This spontaneous case was reported by a consumer and describes the occurrence of NECK PAIN (Neck pain) and PAIN IN JAW (Jaw pain) in a 69-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 002B21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included MULTIVITAMIN [VITAMINS NOS], ACETYLSALICYLIC ACID (BABY ASPIRIN), COLECALCIFEROL (VITAMIN D3) and LEVOTHYROXINE SODIUM (SYNTHROID) for an unknown indication.   On 22-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In March 2021, the patient experienced NECK PAIN (Neck pain) and PAIN IN JAW (Jaw pain). At the time of the report, NECK PAIN (Neck pain) and PAIN IN JAW (Jaw pain) outcome was unknown.            No treatment information was reported. The patient stated that he was worried that his first dose was invalid because he had no reaction at all and there was a power outage at the vaccine site due to a grid power loss in his state at the time of 1st dose.  The lot no for first dose was provided as CR7M20A CR may not be correct.   This case was linked to MOD-2021-386949 (Patient Link).
what seems to be  MYOSITIS in hip muscles starting on left side proceeding to generalized hip area .... mild weakness...more prominent on left side combined with fatigue. symptoms appear to be lessening slowly.
Presented to me 11/25/17 complaining of redness, swelling, pain at site of VARIVAX injection. Diagnosed with skin abscess treated with oral and topical antibiotics.
Shot great - on Friday. Apr 9th,  midnight between apr 15 & Apr 16, developed red itchy rash left arm injection site.  By morning of Apr 16 did not feel well but was not running a fever YET.  Felt bad all day, got worse in evening Apr 16th.  Went to bed early arm red hit and swollen.  Took arm temperature 103!  Took head temperature 99 which within hours rose to 101.7.  Chills, extreme tired etc.  by morning fever broke and back to 98.1, felt better.  Rash on arm worse redness spread down to elbow and under arm.  Began developing chicken pox herpes type blisters around injection site and well developed many blisters by April 18th - I have pictures!  Felt well but arm sore and looked worse than it was.  GET THIS (very important) blisters continued developing many UNTIL I took 5 x L-Lysine  600 mg the morning of Apr 19th at 7:30am - by evening REMARKED DIFFERENCE. Blisters were disappearing at a rapid rate!  Took another 4 x lysine (same as listed above) by morning (less than 24 hours all blisters DISAPPEARED - I have pictures of that too!  It was a remarkable difference and others need to know how easy this was to get rid of!  It was horrible looking before looked like 100 cold sores merging together to absolutely nothing 24 hours after beginning lysine!
Information has been received from a registered nurse concerning her granddaughter who on 29-DEC-2008 was vaccinated orally with 2 ml of the first dose of ROTATEQ (Lot number not provided).  On 02-JAN-2009 the patient experienced severe diarrhea described as loose orange stools.  The patient also developed a decrease in appetite (onset not reported).
tinnitus; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of TINNITUS (tinnitus) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced TINNITUS (tinnitus). At the time of the report, TINNITUS (tinnitus) outcome was unknown.            No Concomitants are provided. No Treatment information provided.   Reporter did not allow further contact
Pt vaccinated with MMR/HIB developed fever X 24hrs w/mild erythema rash upper trunk - Macular papular on 27AUG90; Reevaluated- fever, fading of rash. Short periods of starring, face color changed & dazed state seizure were short. See WORM.
CHILD RECIEVED VARIVAX ON 09-27-96 AND NOW HAS THE CHICKEN POX
7-8 days after I had the vaccine, it started getting itchy, puffy, and very not at the injection site. I would scratch one in a while
Feeling EXTREME dizziness and nausea that does not let up or subside. Unable to stand. feeling dizzy. Sudden whole body heating up. Face turns red. Symptoms do not get better.
Chills; Achiness; Tiredness; Felt hot; Didn't feel good; I don't know if had fever I checked but I was sweaty; This is a spontaneous report from a contactable consumer, the patient. A 85-year-old female patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, solution for injection, lot number: EN6200), dose 2 via an unspecified route of administration on an unspecified date as dose 2, single (at the age of 85-year-old) for COVID-19 immunization. Medical history included ongoing hypertension, anaemia, blood cholesterol abnormal, cardiac disorder and stent placement. Concomitant medication included rosuvastatin calcium (CRESTOR) taken for blood cholesterol abnormal. Patient take unspecified high blood pressure medications. Patient was about to take Prolin shot for bones. but was advised to wait for 2 weeks. She asked if it was okay to take it afterwards. It was reported that the patient got the vaccine, second one on Monday. Monday, she felt okay and on Tuesday felt okay till the afternoon and then started getting the chills and achy and tired and then felt hot, did not know if had fever patient checked but she was sweaty when went back to lay down on bed so that lasted from about 3 o'clock in the afternoon and then the next morning which would have been Wednesday morning. The patient felt pretty good but not exactly like she should but then felt pretty good that day and then yesterday that was Thursday around 2 or 3 o'clock the same time patient started getting the same things, the chills and the achiness and tiredness and just did not feel good and then this morning patient was felt better but just tired. Patient reported vaccination date as The 8th, March 8th. Consumer stated, she think she was 5 feet 3 inches and 140 pounds. The patient did not receive any treatment for the events. The outcome of the events was unknown.  No follow-up attempts were possible. No further information was expected.
severe nerve pain on upper limbs and torso; Constant tingling sensation on fingers/Tingling sensation on the palm; Odd sensation on the torso; ischemic sensation and cold sensation; This spontaneous case was reported by a consumer and describes the occurrence of NEURALGIA (severe nerve pain on upper limbs and torso), PARAESTHESIA (Constant tingling sensation on fingers/Tingling sensation on the palm), FEELING ABNORMAL (Odd sensation on the torso) and FEELING COLD (ischemic sensation and cold sensation) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Penicillin allergy, Sulfonamide allergy, Allergy to antibiotic (cephalosporins), Latex allergy, Allergy to nuts, Asthma and Stenosis. Concomitant products included FLUTICASONE FUROATE, VILANTEROL TRIFENATATE (BREO ELLIPTA) and MONTELUKAST for Asthma, ALENDRONATE SODIUM (ALENDRONATE) and CALCIUM CARBONATE, COLECALCIFEROL (VITAMIN D 2000) for Osteoporosis.    On 07-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced NEURALGIA (severe nerve pain on upper limbs and torso), PARAESTHESIA (Constant tingling sensation on fingers/Tingling sensation on the palm), FEELING ABNORMAL (Odd sensation on the torso) and FEELING COLD (ischemic sensation and cold sensation). The patient was treated with TRAMADOL for Pain, at a dose of 3 dosage. On 01-Sep-2020, NEURALGIA (severe nerve pain on upper limbs and torso) had resolved. At the time of the report, PARAESTHESIA (Constant tingling sensation on fingers/Tingling sensation on the palm) and FEELING ABNORMAL (Odd sensation on the torso) had not resolved and FEELING COLD (ischemic sensation and cold sensation) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       Other concomitant reported include Kevoceturuzine 5mg,1d through oral route for allegy.   Most recent FOLLOW-UP information incorporated above includes: On 15-Aug-2021: Significant follow up appended
Fatigue-18 hours, chills-Intermittent over 18 hours, sweats-Intermittent over 18 hours, headache-Light to Medium over 12 hours, arm soreness-36 hours and counting  Taken ibuprofen to help with arm soreness over the last 2 days
woke up throwing up at 10 minutes to 1:00 AM; nauseous all day; This spontaneous case was reported by a consumer and describes the occurrence of VOMITING (woke up throwing up at 10 minutes to 1:00 AM) and NAUSEA (nauseous all day) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. L025A21A) for COVID-19 vaccination.     Concurrent medical conditions included Hypercholesterolemia. Concomitant products included INSULIN for an unknown indication.    On 05-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Mar-2021, the patient experienced VOMITING (woke up throwing up at 10 minutes to 1:00 AM) and NAUSEA (nauseous all day). On 06-Mar-2021, VOMITING (woke up throwing up at 10 minutes to 1:00 AM) had resolved. On 07-Mar-2021, NAUSEA (nauseous all day) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment medications were reported. Concomitant medications include: hypercholesterolemia medicine   Most recent FOLLOW-UP information incorporated above includes: On 03-May-2021: Reporter's details were updated
Patient received first dose of vaccine and about 5 to 10 minutes later patient fainted and hit her head while waiting in pharmacy area after receiving the shot. She quickly regained consciousness and two pharmacists had her sit on ground to elevate her legs. Also gave her water. Had her stay in pharmacy waiting area until she was ok to leave.
This is a spontaneous report from a contactable consumer (parent). A female patient of an unspecified age received the first dose of TRUMENBA, via an unspecified route of administration on 04Feb2019 at a single dose for immunisation. The patient's medical history and concomitant medications were not reported. The reporter's daughter (patient) received her first dose of meningococcal group B rlp2086 on Monday, 04Feb2019, and she noticed yesterday afternoon (04Feb2019) she had a large red circle around the injection site. The reporter took the patient back to the doctor today (05Feb2019) and was told that it was a local reaction that can happen with any shot and not a reaction to the meningococcal group B rlp2086 vaccine itself. The outcome of the event was unknown.
has raised bumps on her chest; terrible rash; burning; itching; This spontaneous case was reported by a consumer and describes the occurrence of BURNING SENSATION (burning), PRURITUS (itching), SWELLING (has raised bumps on her chest) and RASH (terrible rash) in a 78-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 038K20A) for COVID-19 vaccination.     No Medical History information was reported.    On 05-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-Feb-2021, the patient experienced BURNING SENSATION (burning), PRURITUS (itching) and RASH (terrible rash). On 03-Mar-2021, the patient experienced SWELLING (has raised bumps on her chest). At the time of the report, BURNING SENSATION (burning), PRURITUS (itching) and RASH (terrible rash) was resolving and SWELLING (has raised bumps on her chest) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not reported  Treatment information was not provided
This spontaneous case, initially received on 01-Jun-2017, was reported by other health professional (registered nurse) and concerns students in an academic campus, who all received flu vaccine. This case deals with sixteenth of 23 reports. From 03-Oct-2016 to 04-Oct-2016, 176 students were vaccinated with FLUCELVAX in the total of 258 students in the campus. In the spring of 2017, an outbreak of the flu occurred and lasted for approximately 10 days. The reporter stated that, from 13-Apr-2017 to 18-Apr-2017, they treated 22 students with flu and among them 5 students had the vaccine on campus. In the beginning of 18-Apr-2017, they treated another 23 students with flu symptoms and only 3 of those had not received the flu vaccine. The students were tested positive for influenza A via rapid flu test with nasopharyngeal swab. This case concerns 17-years-old patient of unspecified gender. On 03-Oct-2016, the patient received FLUCELVAX QIV (dose, route of administration and anatomical location: not reported, batch number: 185888, expiration date: 31-May-2017). On 22-Apr-2017, the patient was tested positive for influenza A via rapid flu test with nasopharyngeal swab (characterized as vaccination failure). Based on the investigation performed, it can be concluded that FLUCELVAX 185888 was manufactured in compliance with the approved internal procedures and in accordance with the quality requirements. No evidence was found that the LOE complaint was the result of the Fill Finish or Bulk manufacturing process and no trends were identified for the batch number 185888, or any other FLUCELVAX QIV batches from the 2016-2017 FLUCELVAX Commercial season. Therefore, no internal root cause could be confirmed. Outcome of influenza A virus infection and vaccination failure was not reported. The reporter did not provide seriousness assessment. The reporter stated that, the students received flu vaccine had less severe symptoms than those who had not received the flu vaccine. Batch review report (QAIR number: 1022277) received from quality assurance department on 29-Jul-2017: QA investigation results were updated. The narrative was amended accordingly. Non-significant case correction received on 10-Aug-2017: Narrative and case comment were corrected.
Possible misadministration of PENTACEL vaccine. Vaccine inventory audit discovered 1 remaining vial of the PENTACEL diluent (DTaP/ Polio solution portion) so it is assumed that an incorrect diluent was used to mix with the Hib powder portion of the vaccine rendering the vaccine not valid. It is unclear which child in the month of May received the invalid dose, so all families are being notified of the possible error and offered re-vaccination.
Lichenoid dermatitis; Allergic to the mRNA (Moderna); This spontaneous case was reported by a consumer and describes the occurrence of CHILLBLAINS (Chilblains), LICHENOID KERATOSIS (Lichenoid dermatitis) and ALLERGY TO VACCINE (Allergic to the mRNA (Moderna)) in a female patient of an unknown age who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 immunisation.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced CHILLBLAINS (Chilblains), LICHENOID KERATOSIS (Lichenoid dermatitis) and ALLERGY TO VACCINE (Allergic to the mRNA (Moderna)). At the time of the report, CHILLBLAINS (Chilblains), LICHENOID KERATOSIS (Lichenoid dermatitis) and ALLERGY TO VACCINE (Allergic to the mRNA (Moderna)) outcome was unknown.        The action taken with mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown) was unknown.       Concomitant medication not reported.   The patient was allergic to the mRNA vaccines (got COVID fingers: biopsy, x-rays, derm consults X 2, rheumatology consult, heme-onc consults related with dxs lichenoid dermatitis, chilblains, etc and a second opinion from a dermatologist said that patient was probably allergic to the mRNA (Moderna) COVID vaccines.  Treatment medication not reported.  Company comment: This spontaneous case concerns a female patient of unknown age with no reported medical history, who experienced the non-serious unexpected which occurred unknown days after administration of a dose of mRNA-1273.222 bivalent vaccine. It was reported that the patient was probably allergic to the mRNA (Moderna) COVID vaccines. Treatment details are not reported. Event outcome was unknown. The benefit-risk relationship of mRNA-1273.222 bivalent vaccine is not affected by this report.   Reporter did not allow further contact
mild nausea; dizziness; sweating; Little appetite or desire for food; Head feels "off" or slightly foggy; chills; This is a spontaneous report received from a contactable consumer, the patient.  A 73-years-old non-pregnant female patient received 1st dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; batch/lot number: EN 6201) via an unknown route in left arm on 04Mar2021 at 12:15 PM for COVID-19 immunization (at the age of 73-years). The patient did not have any medical history and the patient was not allergic to medications, food or other products. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient was not diagnosed with COVID-19 prior to vaccination and the patient was not tested for COVID-19 since the vaccination. Concomitant medication included Naproxin (MANUFACTURER UNKNOWN) for an unknown indication. The patient received this medication within 2 weeks of vaccination and the exact therapy dates were not provided. The patient woke up at morning on 16Mar2021 (12 days after 1st dose) at 08:30 AM with dizziness, sweating and mild nausea. The patient's temperature was normal. The patient felt fine the night before and slept well. The nausea continued for 3 hours. The patient developed chills after sweating subsided and the chills have continued for the past six hours. The patient was having little appetite or desire for food. The patient's head did not hurt but felt "off" or slightly foggy. No therapeutic measures were taken as a result of these events. On 16Mar2021, the events dizziness and sweating resolved within 30 minutes of waking. The patient was recovering from the events mild nausea, chills, little appetite or desire for food and head did not hurt but felt "off" or slightly foggy. No follow-up attempts are needed. No further information is expected.
Facial swelling and hives, onset about 3 hours post-injection. Managed with diphenhydramine 25mg every 4-6 hours for 4 days. Mostly resolved within 2 days with lingering symptoms resolving within 5. Headache, fever (100.3), body pain, swollen lymph nodes in armpit, brain fog onset within 12 hours. Resolved within 36 hours with sleep.
This is a spontaneous report obtained from a contactable physician through a Pfizer sales representative. An adolescent male patient of an unspecified age and ethnicity received, on an unspecified date, TRUMENBA at 0.5 ml, single dose. Relevant medical history and concomitant medications were unknown. On an unspecified date, the patient experienced pericarditis. The patient recovered from the adverse event at the time of this report. The reporting physician considered that the reported event was due to TRUMENBA.
2-3 days post vaccine pt developed congestion and lost of taste and smell. Went to convenient care on 4/11/21 and tested positive for COVID.
606 doses were given after expiration date; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (606 doses were given after expiration date) in a 37-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 043B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 06-Oct-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 06-Oct-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (606 doses were given after expiration date). At the time of the report, EXPIRED PRODUCT ADMINISTERED (606 doses were given after expiration date) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant and treatment medication was not reported. No adverse events reported. No temperature excursion of the product was reported. Date place in refrigerator: 17-Nov-2021
Patient presented to the ED due to shortness of breath and chest pain stating that the symptoms developed yesterday after receiving COVID-19 immunization.  Patient stated that she has taken multiple albuterol and Benadryl doses yesterday. Pain is located at the center of the chest and bilateral ribs (right more than left). When taking deep breaths the pain increases.
Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) in a 70-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 07-Jan-2021 at 10:16 AM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 07-Jan-2021 at 10:16 AM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). In 2021, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The age of patient was provided as 70.21 years.  No concomitant medications were reported.  Batch number 027L20A underwent temperature excursion on 07-Jan-2021 with temperature 34 degrees Fahrenheit at 09:00 AM. The vial was initially moved to the fridge on 05-Jan-2021 and proposed beyond use date was 27-Jan-2021. Product moved to clinic on 07-Jan-2021. Vials were sent to clinic.  Vial was in cooler storage and was not in frozen storage during high-pace COVID-19 vaccination at around 2021. Vials were only punctured right before administration. Vaccines were not frozen at time of administration. It was reported that each time a vial was put into a cooler, sometimes there was a period of 1 hour or 1 hour and a half approximately, when temperature data logger registered a temperature of 34- or 35-degree Fahrenheit. Temperature recordings were taken using a traceable temperature monitor at every hour.  No treatment medications were reported.   This case was linked to MOD-2022-566976 (Patient Link).
pt recv vax 16MAR99 1045AM & started uncontrollable crying approx 12AM 17MAR99;high fever started approx 430AM on 17MAR99;
Soreness at injection site and fatigue onset about 8 hours post injection. Body aches, chills, and headache onset about 15 hours post injection.